Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Shares Issued (2021 - 2025)

Historic Shares Issued for Gain Therapeutics (GANX) over the last 4 years, with Q3 2025 value amounting to -$5.1 million.

  • Gain Therapeutics' Shares Issued fell 51182560000.0% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41744.0, marking a year-over-year decrease of 9518.28%. This contributed to the annual value of $113800.0 for FY2024, which is 9708.21% down from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Shares Issued is -$5.1 million, which was down 51182560000.0% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Shares Issued peaked at $42.6 million during Q1 2021, and registered a low of -$5.1 million during Q3 2025.
  • Its 4-year average for Shares Issued is $3.9 million, with a median of $454935.0 in 2023.
  • The largest annual percentage gain for Gain Therapeutics' Shares Issued in the last 5 years was 1956850.83% (2025), contrasted with its biggest fall of 51182560000.0% (2025).
  • Quarter analysis of 4 years shows Gain Therapeutics' Shares Issued stood at $42.6 million in 2021, then plummeted by 98.23% to $752767.0 in 2023, then tumbled by 100.0% to -$1.0 in 2024, then tumbled by 511825400.0% to -$5.1 million in 2025.
  • Its Shares Issued stands at -$5.1 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.5 million for Q1 2025.